Medicare AdvantageCoverageMedium impact
MA08.164a, Rozanolixizumab-noli (Rystiggo)
Independence Blue Cross·Neurology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.164a for Rozanolixizumab-noli (Rystiggo) has been reissued with updates. This is a fresh 1-day-old policy that may affect coverage or billing requirements for this specialty medication used to treat myasthenia gravis.
Action Required
By May 28, 2025: Billing team must review the full updated policy MA08.164a for Rozanolixizumab-noli (Rystiggo) on the IBX Medicare Advantage portal to understand any changes to coverage criteria, prior authorization requirements, or billing procedures. Update billing system and provider documentation requirements accordingly for Medicare Advantage patients requiring this medication.